Company news
4basebio Plc (LSE:4BB) news
Every 4basebio Plc press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
4basebio and Genezen Enter into Strategic Col...
August 26, 2026
4basebio Plc - Grant of Options & Director/PDMR Dealing
July 22, 2026
Director Appointment
July 8, 2026
4basebio Plc - Result of AGM & Issue of Options
June 30, 2026
Notice of Investor Presentation
June 16, 2026
4basebio Appoints Dr. Jeff Coller to Strategi...
June 15, 2026
Notice of Annual General Meeting
June 5, 2026
4basebio Plc - Director Dealing
May 22, 2026
4basebio Plc - 4basebio Signs Clinical Supply Agreement to Support Phase II Clinical Trial
May 20, 2026
Appointment of Chief Financial Officer and Bo...
May 14, 2026
4basebio Launches Enzymatic ssDNA Platform
May 11, 2026
Lease of Manufacturing Facility
March 31, 2026
Appointment of COO
March 12, 2026
4basebio strengthens commercial leadership, promoting Christine Wolosin to Chief Commercial Officer
March 3, 2026
Leadership Changes
February 10, 2026
Synthetic opDNA® utilised in Phase I/II US cl...
October 27, 2025
Result of Extraordinary General Meeting
October 10, 2025
Director Dealing
September 30, 2025
Half-year Report
September 29, 2025
Employee Long Term Incentive Plan and Issue o...
July 22, 2025
Director Appointment, Board Change
July 8, 2025
Holding(s) in Company
July 3, 2025
4basebio Introduces New Branding to Reflect Next Phase of Growth Enabling Development of Advanced Genetic Therapies
July 1, 2025
Result of AGM
June 27, 2025
Exercise of Options
June 25, 2025
Final Results and Notice of AGM
May 27, 2025
4basebio Receives GMP Licence for its UK DNA ...
April 2, 2025
RBC Capital Markets initiates research covera...
March 14, 2025
Director's Dealing
March 3, 2025
Appointment of Chief Commercial Officer
January 8, 2025
Directorate Change
December 17, 2024
Appointment of Joint Corporate Broker
November 14, 2024
Completion of Strategic Investment
November 12, 2024
Update re Equity Issuance, Secondary Sale and...
September 9, 2024
Strategic Advisory Board & Appointment of Dir...
August 8, 2024
£40.0m Equity Issuance and £29.4m Secondary S...
July 29, 2024
4basebio announces the supply of its opDNA™ D...
April 10, 2024
4basebio client's Phase I clinical trials for...
March 21, 2024
4basebio awarded tender to deliver research a...
March 1, 2024
Directors' Dealings
February 5, 2024
Long-Term Incentive Plan and Exercise of Opti...
February 2, 2024
Grant received from the Bill and Melinda Gate...
August 1, 2023
Neomatrix Product Supply Agreement
May 24, 2023
New lease and expansion of manufacturing capacity
April 3, 2023
Exercise of Options and Issue of Equity
February 9, 2023
Further re Conversion to UK PLC
July 23, 2021
Conversion to UK PLC
July 21, 2021
Director/PDMR Shareholding
July 1, 2021
Application filed for protected linearised synt...
June 22, 2021
Annual General Meeting 2021
June 18, 2021